Condition: Hidradenitis Suppurativa · Sponsor: Novartis Pharmaceuticals
The aim of this study is to generate real-world evidence to fill knowledge gaps regarding the response to secukinumab in patients with moderate to severe HS, its treatment patterns, the clinical characteristics of patients on secukinumab, healthcare resource utilization and the economic impact of HS in Italy.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Ancona, AN, Italy | Recruiting |
| Novartis Investigative Site | Bari, BA, Italy | Recruiting |
| Novartis Investigative Site | Brescia, BS, Italy | Recruiting |
| Novartis Investigative Site | Cona, FE, Italy | Recruiting |
| Novartis Investigative Site | Florence, FI, Italy | Recruiting |
| Novartis Investigative Site | Genova, GE, Italy | Recruiting |
| Novartis Investigative Site | Lecce, LE, Italy | Recruiting |
| Novartis Investigative Site | Messina, ME, Italy | Recruiting |
| Novartis Investigative Site | Milan, MI, Italy | Recruiting |
| Novartis Investigative Site | Rozzano, MI, Italy | Recruiting |
| Novartis Investigative Site | San Donato Milanese, MI, Italy | Recruiting |
| Novartis Investigative Site | Palermo, PA, Italy | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07543419